Development of an independent MU calculation software for radiotherapy treatments with stereotactic cones-Reference-Cited by-同舟云学术

Development of an independent MU calculation software for radiotherapy treatments with stereotactic cones

Published:2022-02-15 Issue:4 Volume:23 Page:
ISSN:1526-9914
Container-title:Journal of Applied Clinical Medical Physics
language:en
Short-container-title:J Applied Clin Med Phys

Author:

Campos Guilherme Filipe Pinto¹^ORCID,Souto Ana Catarina Santos²³,Lencart Joana Borges²³,Cunha Luís Paulo Teixeira²³,Dias Anabela Gregório²³^ORCID

Affiliation:

1. Department of Physics and Astronomy Faculty of Sciences University of Porto Porto Portugal

2. Medical Physics Radiobiology and Radiation Protection Group IPO Porto Research Centre (CI‐IPOP) Portuguese Oncology Institute of Porto (IPO Porto) Porto Portugal

3. Medical Physics Department Portuguese Oncology Institute of Porto (IPO Porto) Porto Portugal

Publisher

Wiley

Subject

Radiology, Nuclear Medicine and imaging,Instrumentation,Radiation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/acm2.13542

Reference13 articles.

1. Verification of monitor unit calculations for non-IMRT clinical radiotherapy: Report of AAPM Task Group 114

2. TatliH YucelD YilmazS FaydaM.Development of independent MU/treatment time verification algorithm for non‐IMRT treatment planning: a clinical experience.2018;090001.https://doi.org/10.1063/1.5025987

3. Comprehensive QA for radiation oncology: Report of AAPM Radiation Therapy Committee Task Group 40

4. The Royal College of Radiologists Society and College of Radiographers Institute of Physics and Engineering in Medicine NPSA and BI of R.Towards Safer Radiotherapy.The Royal College of Radiologists;2008.

5. International Atomic Energy Agency.Lessons learned from accidental exposures in radiotherapy.2000.https://www‐pub.iaea.org/MTCD/Publications/PDF/Pub1084_web.pdf. Accessed May 26 2021.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment plan prescreening for patient-specific quality assurance measurements using independent Monte Carlo dose calculations;Frontiers in Oncology;2022-11-07